Health Updates

Flaxseed and Hesperidin Supplements Show Promising Results in NAFLD Study

A recent study revealed that having supplementation with hesperidin and flaxseed lead to better glucose and lipid metabolism, while concurrently reducing inflammation and hepatic steatosis in patients with NAFLD or non-alcoholic fatty liver disease.


Photo: Flaxseed | InStyleHealth

The study included 100 NAFLD patients who were assigned to one of four groups: control, 30-g whole flaxseed powder, 1-g hesperidin supplementation, and a combination of both flaxseed and hesperidin. All groups also joined in a lifestyle change program. Results included changes in anthropometric measurements, glucose, and lipid profiles, inflammatory markers, hepatic steatosis, and fibrosis.


All the subjects of the trial, saw drastic improvements in liver function biomarkers, with significant changes in alanine aminotransferase and gamma-glutamyl transferase by the end of the trial period.


Liver fat content also decreased to a greater extent when lifestyle modification was combined with either or both supplements. Flaxseed alone or when combined with hesperidin, significantly reduced liver fibrosis.


Hepatic steatosis decreased by at least 40 percent in all three intervention, groups, as opposed to the 22-percent reduction in controls after 12 weeks of intervention of the subject group.


“In the current study, we assessed the superiority of two dietary supplements to common lifestyle modifications in NAFLD management. The results showed that taking hesperidin or flaxseed or a combination can increase the effectiveness of lifestyle modifications in NAFLD management,” the researchers said. This simply translates the efficacy of flax seeds benefits for fatty liver.


There are also significant beneficial effects of the test supplements on other factors such as blood glucose, insulin, insulin resistance, triglycerides, total cholesterol, high-sensitivity C-reactive protein, and tumor necrosis factor α, that were found according to the researchers.

Previous Post Next Post
/*News Ticker*/